Lioudis M, Zhou X, Davenport E, Nunna S, Krasa HB, Oberdhan D, Fernandes AW. Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis. BMC Neurol. 2023 Jun 22;24:182. doi: 10.1186/s12882-023-03247-6
Giner-Soriano M, Marsal JR, Gomez-Lumbreras A, Morros R. Risk of ischaemic stroke associated with antiepileptic drugs: a population-based case-control study in Catalonia. BMC Neurol. 2021 May 24;21(1):208. doi: 10.1186/s12883-021-02237-1
Giner-Soriano M, Marsal JR, Gomez-Lumbreras A, Morros R. Risk of ischaemic stroke associated with antiepileptic drugs: a population-based case-control study in Catalonia. BMC Neurol. 2021 May 24;21(1):208. doi: 10.1186/s12883-021-02237-1
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Matlis S, Boric K, Chu CJ, Kramer MA. Robust disruptions in electroencephalogram cortical oscillations and large-scale functional networks in autism. BMC Neurol. 2015 Jun 27;15:97. doi: 10.1186/s12883-015-0355-8.
Meyers JL, Davis KL, Yu YF. Stroke and transient ischemic attack in the long-term care setting: patient characteristics, medication treatment, and length of stay. Consult Pharm. 2011 Mar 1;26(3):170-81.
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Hutchison RW, Anastassopoulos K, Vallow S, Mordin M, Olson W, Hewitt D, Sikirica V. Intravenous patient-controlled analgesia pump and reservoir logistics: results from a multicenter questionnaire. Hosp Pharm. 2007 Nov 1;42(11):1036-44.